Eir Ventures, a Nordic-focused investment firm and client of the firm, co-led, together with Soleus Capital, a $64 million equity investment into Galecto, Inc., a Copenhagen, Denmark and Boston, US-based biotechnology company focused on the development of novel treatments for fibrosis and cancer. ELG represented Eir in its review and negotiation of a suite of investment documents, including the securities purchase agreement.
